Initiation versus Cessation Control Policies: Deriving Optimal Resource Allocation Strategies to Decrease Smoking Prevalence Under a Fixed Budget

Ruoyan Sun and David Mendez

Abstract

Background. Over several decades the tobacco control community has recommended and implemented smoking initiation and cessation interventions to reduce the smoking toll. It is necessary to study the combined effect of these interventions to allocate resources optimally. However, there is a paucity of studies that address the right combination of initiation and cessation policies over time to reduce smoking prevalence. Objective. To derive optimal trajectories of initiation and cessation interventions that minimize overall smoking prevalence over a specified period while satisfying a budget constraint. Methods. Using an established dynamic model of smoking prevalence, we employ an optimal control formulation to minimize overall smoking prevalence within a specified time period. The budget constraint is handled through an iterative application of a penalty function on above-budget expenditures. We further derive the optimal cost ratio of initiation versus cessation programs over time. To parameterize our model, we use results from two empirical interventions. The demographic data are from the National Health Interview Survey in the United States. Results. For our example, our results show that the optimal cost ratio (initiation over cessation) starts around 2.02 and gradually increases to 5.28 in 30 years. Smoking prevalence decreases significantly compared with the status quo, 8.54% in 30 years with no interventions versus the estimated 6.43% with interventions. In addition, the optimal units of initiation and cessation interventions increase over time. Conclusions. Our model provides a general framework to incorporate policy details in determining the optimal mix of smoking interventions.

Keywords

Optimal control, tobacco control, smoking prevalence, smoking cessation

Cigarette smoking has remained as the leading preventable cause of disease and premature death in the United States. It can lead to many adverse health consequences such as lung cancer, cardiovascular diseases, and respiratory diseases.1–3 In the United States alone, in 2015, more than 16 million individuals lived with a smoking-related disease. According to the estimates given by the 2014 Surgeon General’s report, the annual number of smoking-attributable deaths is around 480,000 and has stayed above 400,000 for more than a decade.4 Besides

Department of Health Management and Policy, University of Michigan Ann Arbor, Ann Arbor, Michigan. The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The author(s) received no financial support for the research, authorship, and/or publication of this article.

Corresponding Author
Ruoyan Sun, Department of Health Management and Policy, University of Michigan Ann Arbor, 1415 Washington Heights, Ann Arbor, MI 48109, USA; Telephone: (734) 764-0287; (sunry@umich.edu).
mortality, smoking imposes a substantial financial burden on society. Smoking-attributable economic costs resulting from loss of productivity, premature deaths, and direct medical cost added up to around $300 billion over the 2009 to 2012 period.\textsuperscript{4,5} To private employers in the United States, a smoking employee costs an extra $5,816 per year, considering excess absenteeism, presenteeism, and lost productivity due to smoking breaks, excess health care costs, and pension benefits.\textsuperscript{6}

The primary focus of tobacco control policies in the United States has been to reduce the number of smokers. Reducing smoking prevalence can be achieved either by encouraging smokers to quit or by preventing nonsmokers from taking up the habit. Smoking cessation interventions aim at the first goal while smoking initiation interventions target the latter. Cessation programs can be divided into two categories: pharmacological and nonpharmacological interventions. Pharmacological interventions are those in which smokers take prescribed drugs to help with their nicotine withdrawal syndromes. Popular treatments include nicotine-replacement treatment, bupropion, and varenicline.\textsuperscript{7,8} Nonpharmacological interventions usually involve motivational interviews and counseling as well as cognitive behavioral therapy.\textsuperscript{9,10} Scholars have identified a few barriers for successful nonpharmacological interventions, including lack of social support, cultural norms, and stressful working/living situations.\textsuperscript{11,12} Initiation/prevention programs aimed at reducing the risk of youth becoming smokers. Some popular programs include cigarette taxation, mass media campaigns, and school-based education programs.\textsuperscript{13–16} Studies show that smoking initiation occurs during teenage and young-adulthood years, but is very rare after age 24 years.\textsuperscript{17,18} As a result, smoking initiation programs mainly target teenagers at school.

Smoking prevalence in the United States in 2015, after 50 years of smoking control efforts, has decreased to 15.1% from 43% in 1964.\textsuperscript{19} To accelerate the eradication of the smoking epidemic, more efficient ways to implement smoking interventions are needed. Previous studies reveal that initiation and cessation programs are implemented and evaluated independently. Few studies look at the combined impact of multiple interventions targeting both initiation and cessation. The right combination of interventions could accelerate the process of reducing smoking prevalence while allocating limited resources efficiently. However, given the constant change of the environment in which these policies will act, there is a need to anticipate those changes and propose interventions that will adapt over time to this dynamic environment.

Optimization techniques, such as Optimal Control, can be useful in deriving appropriate solutions to this dynamic problem. Optimal control theory deals with problems of finding the paths of control variables that satisfy certain optimality criterion. In the context of dynamic models, the solutions represent a path for the control variables over time. Some scholars have applied optimal control theory to investigate empirical policies. For example, Juusola and Brandeau used optimal control to determine the best mix of investment in HIV treatment and prevention given a fixed budget. Their model maximizes the net present quality-adjusted life years.\textsuperscript{20} Similarly, Basu and Kiernan investigated how financial incentives motivate health behavior changes by optimizing marginal return on investments.\textsuperscript{21} When we deal with smoking policies, we can figure out the best combination of initiation and cessation programs over time to minimize prevalence given a budget constraint. To the best of our knowledge, we are the first study to adopt optimal control techniques to address the problem of reducing smoking prevalence over time while subjected to a budget constraint.

The organization of this article is as follows. First, we propose an optimal control dynamic model of ordinary differential equations (ODEs) and solve it analytically. Second, we identify and discuss an initiation and a cessation intervention to use as controls in the model. We then parameterize the model and solve it numerically for optimal trajectories. Finally, we present and discuss our results.

Methods

Theoretical Model

Based on previous work,\textsuperscript{22,23} we employ the following expression to represent the path of smoking prevalence over time:

\[
\dot{S} = I(t) - (\mu(t) + \nu(t))S(t)
\]

where \(S(t)\) stands for the number of smokers in the population at time \(t\), \(I(t)\) is the number of new smokers at time \(t\), and \(\mu(t)\) and \(\nu(t)\) are the time-variant death and smoking cessation rates, respectively.

The original model has \(S\) and \(I\) as number of people while \(\mu\) and \(\nu\) are rates. Assuming a constant population of size \(M\) and dividing by \(M\) on both sides of expression (1),

\[
\frac{\dot{S}}{M} = \frac{I(t)}{M} - (\mu(t) + \nu(t))\frac{S(t)}{M},
\]
where
\[ s(t) = \frac{S(t)}{M} \]
is the time-variant smoking prevalence and
\[ i(t) = \frac{I(t)}{M} \]
is the initiation rate. Because we assume \( M \) to be constant,
\[ \dot{s} = \frac{d(s(t))}{dt} = \frac{1}{M} dS(t) = \frac{1}{M} \dot{S}. \]
We can write the transformed Equation (1) as
\[ \dot{s} = i(t) - [\mu(t) + \nu(t)]s(t). \quad (2) \]

Empirical policies are generally designed with a proposed goal and a budget constraint. To incorporate these characteristics, our model aims to minimize the overall toll of smoking prevalence over time, subject to a budget constraint. In order to construct a performance measure that takes both factors into account, we assign weights to these two aspects. \( \sigma_1 \) is the weight assigned to smoking prevalence and \( \sigma_2 \) is the one for cost: \( \sigma_1 + \sigma_2 = 1 \) and \( \sigma_1, \sigma_2 \geq 0 \). The values of weights are determined by the policy as well as the corresponding budget. If the policy has no budget constraint, then \( \sigma_1 = 1 \) and \( \sigma_2 = 0 \). If the policy aims at reducing smoking prevalence with a budget constraint, then weights can be determined retrospectively by calculating the total cost over time and penalizing over-expenditures. The algorithm can be divided into two steps. The first step is to calculate the total cost retrospectively by summing up the area under the cost curve. In the second step, through adjusting weights, we can write a loop to find the minimum weight in front of costs that satisfy the proposed budget constraints. In this way, we can decrease smoking prevalence efficiently while satisfying the budget constraint. In addition, reducing cost requires us to include costs of interventions. \( \gamma_1 \) is the price per unit of initiation intervention and \( \gamma_2 \) is the unit price of cessation intervention \( \gamma_1, \gamma_2 > 0 \).

After defining our performance measure, we add some constraints to our model. Besides Equation (2), we have two more equations: \( i(t) = \alpha_0 + \alpha_1u_1(t) \) and \( \mu(t) + \nu(t) = \beta_0 + \beta_1u_2(t) \). The death rate \( \mu(t) \) is assumed to be constant over time and we include its value in \( \beta_0 \). We denote \( \mu + \nu(t) \) as \( \theta(t) \) to simplify the notation. \( u_1(t) \) is the total units of initiation intervention over time and \( u_2(t) \) is the units for cessation intervention over time. Unit here is a technical term; one interpretation for unit is the scope of the intervention. For example, if \( \gamma_1 \) is the cost of one initiation intervention per 1,000 individuals, then we can have \( \mu_1 = 2 \) to represent the cost of an intervention for 2,000 individuals. Similarly, unit can stand for number of interventions. We can implement three interventions of the same size simultaneously and consider the impact as 3 units of one intervention. We have \( \alpha_1 \) and \( \beta_1 \) to represent the effectiveness of interventions in the form of their impact on adult smoking initiation and cessation rates. \( \alpha_0 \) is the initiation rate at \( t_0 \) and \( \beta_0 \) includes both death rate and smoking cessation rate at \( t_0 \).

Now we are ready to write our problem in the mathematical form:
\[
\min_{u_1, u_2 \geq 0} \int_{t_0}^{t_f} \left[ \sigma_1 s(t) + \sigma_2 (\gamma_1^2 u_1^2(t) + \gamma_2^2 u_2^2(t)) \right] dt
\]
subject to
\[
\dot{s} = i(t) - \theta(t) s(t) \\
i(t) = \alpha_0 + \alpha_1 u_1(t) \\
\theta(t) = \beta_0 + \beta_1 u_2(t) \\
\delta_1 + \delta_2 = 1, \quad \delta_1, \delta_2 \geq 0 \\
\gamma_1, \gamma_2 > 0 \\
\alpha_1 < 0, \quad \beta_1 > 0
\]
We can combine the first three constraints into one:
\[ \dot{s} = \alpha_0 + \alpha_1 u_1(t) - (\beta_0 + \beta_1 u_2(t)) s(t) \]
We choose to use the quadratic form for cost to penalize for extreme values. It is also a conventional form to represent cost in optimal control problems. Then we can simplify the above problem into:
\[
\min_{u_1, u_2 \geq 0} \int_{t_0}^{t_f} \left[ \sigma_1 s(t) + \sigma_2 (\gamma_1^2 u_1^2(t) + \gamma_2^2 u_2^2(t)) \right] dt
\]
subject to
\[
\dot{s} = \alpha_0 + \alpha_1 u_1(t) - (\beta_0 + \beta_1 u_2(t)) s(t) \\
\delta_1 + \delta_2 = 1, \quad \delta_1, \delta_2 \geq 0 \\
\gamma_1, \gamma_2 > 0 \\
\alpha_1 < 0, \quad \beta_1 > 0
\]
We obtain the augmented integrand function as
\[ g_u(s(t), u_1(t), u_2(t), p(t)) = \delta_1 s(t) + \delta_2 (\gamma_1^2 u_1^2(t) + \gamma_2^2 u_2^2(t)) + p(t) [s - \alpha_0 + \alpha_1 u_1(t) + (\beta_0 + \beta_1 u_2(t)) s(t)]. \]

Using the Euler-Lagrange equation, we derive the following set of necessary conditions for the optimal solution:
\[
\begin{align*}
2\delta_2 \gamma_1^2 u_1(t) - \alpha_1 p(t) &= 0 \\
2\delta_2 \gamma_2^2 u_2(t) + \beta_1 p(t) s(t) &= 0 \\
\alpha_0 + \alpha_1 u_1(t) &= \beta_0 + \beta_1 u_2(t) s + \dot{s} \\
\delta_1 + p(t) \beta_0 + p(t) \beta_1 u_2(t) - \dot{p} &= 0
\end{align*}
\]

The first two constraints give us the value of \( u_1(t) \) and \( u_2(t) \) in terms of other parameters:
\[
\begin{align*}
u_1(t) &= \frac{\alpha_1 p}{2\delta_2 \gamma_1} \\
u_2(t) &= \frac{\beta_1 p s}{2\delta_2 \gamma_2}
\end{align*}
\]
plugging these values back into the last two ODE constraints, we have
\[
\begin{align*}
\dot{s} &= \alpha_0 + \frac{\alpha_1^2 p}{2\delta_2 \gamma_1} - \beta_0 s + \frac{\beta_1^2 p s^2}{2\delta_2 \gamma_2} \\
\dot{p} &= \delta_1 + \beta_0 p - \frac{\beta_1^2 p s}{2\delta_2 \gamma_2}
\end{align*}
\]

The time-variant optimal control problem we start with now becomes a set of ODE equations with initial and parameter values. One qualitative analysis we can conduct here is to compare if we should invest more in initiation intervention or cessation intervention, aka comparing \( \gamma_1 u_1(t) \) with \( \gamma_2 u_2(t) \). Since we already know the expression of \( u_1(t) \) and \( u_2(t) \), we plug these values into the equation:
\[
\begin{align*}
\gamma_1 u_1 &= \frac{-\alpha_1 p}{2\delta_2 \gamma_1} \\
\gamma_2 u_2 &= \frac{\beta_1 p s}{2\delta_2 \gamma_2} \\
\gamma_1 &= \frac{-\alpha_1}{2\delta_2 \gamma_1} \\
\gamma_2 &= \frac{\beta_1 p s}{2\delta_2 \gamma_2}
\end{align*}
\]

Here we have \( p < 0 \) from \( u_1 > 0, \beta_1, \delta_1, \delta_2, \gamma_1, \gamma_2 > 0 \) and \( \alpha_1 < 0 \). The reasoning is the following. We know the weights, \( \delta_1 \) and \( \delta_2 \), are always nonnegative by definition, the same for prices, \( \gamma_1 \) and \( \gamma_2 \). \( \alpha_1 \) is the effectiveness of the initiation intervention, which aims at decreasing initiation rate, thus \( \alpha_1 < 0 \). \( \beta_1 \), the parameter measuring the effectiveness of the cessation intervention, should increase the cessation rate by having \( \beta_1 > 0 \). The ratio of
\[
\frac{|\alpha_1| \gamma_2}{\beta_1 \gamma_1 s}
\]
is the optimal proportion of the budget that should be spent on initiation intervention versus cessation intervention.

**Numerical Simulations**

Here we consider one initiation intervention and one cessation intervention in our model to illustrate the optimal path of \( u_1 \) and \( u_2 \) with respect to time. The optimal paths also solve the problem of allocative efficiency over time. This numerical simulation example using empirical results illustrates how our model optimizes intervention units \( u_1 \) and \( u_2 \) over time to minimize smoking prevalence while satisfying a budget constraint. These simulation examples are not intended to be exhaustive or represent implementable interventions, but to illustrate how this method can be used to develop optimal combinations over time to achieve certain goals. Especially how the policies should change over time to achieve these goals.

To parameterize our simulation example, we use the 2014 estimates from the National Health Interview Survey (NHIS; 16.8% smoking prevalence and 0.35% initiation rate). Here we define the initiation rate as the 18 to 24 prevalence taken as a proportion of the entire adult population. We use the permanent cessation rate (net of relapses) of 4.5% estimated by Mendez et al. As our policy example, we use cost and effectiveness values from the 12 + 12 weeks of varenicline treatment for smoking cessation and the US truth campaign for smoking prevention. In our analysis, one intervention unit covers 1 million individuals. This unit size is arbitrary and can be scaled up or down.

The values of \( \alpha_1 \) and \( \beta_1 \) are a bit more complicated. The effectiveness of the interventions needs to be scaled properly to be applied to the entire adult population since smoking prevalence is a population-level measure. We use two sets of demographic data to fit our model, NHIS and NSDUH (National Survey on Drug Use and Health). According to the coding documents for NHIS survey in 2014, the population data used was the 2010 Census. Combining the 2010 Census population size estimates with smoking prevalence from NHIS, we estimate
a total of 39.6 million adult smokers in 2014 and the adult population size is approximated to be 234 million.

Last, we determine the values of $d_1$ and $d_2$. Since $d_2 = 1 - d_1$, we have just one unknown. We assume a total budget of 1 billion dollars over the time span of 30 years. Using the algorithm mentioned earlier, we first start with an initial guess of $d_1$ and calculated the corresponding total cost retrospectively. We found the minimum weight in front of costs that satisfy the proposed budget constraints to be 0.01 in our example. The exact value of the minimum weight changes with respect to the units of cost used.

### Simulations

#### Smoking Initiation Intervention

The truth campaign is a national youth smoking prevention campaign launched by the American Legacy Foundation starting from 2000. The truth campaign is a national tobacco counter-marketing campaign targeted primarily 12- to 17-year-olds. The campaign sent its anti-smoking message by TV commercials, advertisements, promotional items, street marketing, and a website.

Studies evaluating the US truth campaign found that 22% of the overall decline in youth smoking that occurred between 1999 and 2002 can be attributed to the campaign. In addition, the campaign was estimated to prevent 300,000 youth from smoking by 2002. The total cost including travel costs is approximately 324 million dollars in 2002. Using 2014 US dollars, we estimated the per person cost to be 179 dollars.

#### Smoking Cessation Intervention

Among available smoking cessation alternatives, varenicline treatment, commonly branded as Chantix in the United States, is viewed by many as the most effective smoking cessation aid. A randomized, double-blind trial published in 2006 recruited 1210 adult smokers to receive a 12+12 weeks of varenicline treatment. These smokers were assessed after 28 weeks where 603 patients were randomized to varenicline maintenance and 607 randomized to placebo. Researchers found that the 1-year abstinence estimate for the 12+12 weeks of varenicline treatment is 27.7%, compared with the 9.3% with placebo treatment. In addition, the average cost of the course of varenicline treatment was estimated at $603.89 in 2010. Knight and colleagues estimated the treatment cost as the sum of the initial 12 weeks of costs (covering one physician visit and 12 weeks of varenicline) and a further 12 weeks of maintenance therapy (another physician visit and 12 weeks of varenicline) for successful quitters.

Table 1 shows all the parameter values in our simulation example.

### Table 1  Parameter Values in the Simulation Example

| Population | Smoking Initiation Effectiveness of the US Truth Population | Smoking Cessation Rate in 2014 | Death Rate in 2014 | Effectiveness of the 12 + 12 Weeks Varenicline Treatment | Unit Cost of the US Truth | Unit Cost of the 12 + 12 Weeks Varenicline Treatment |
|------------|------------------------------------------------------------|-------------------------------|-------------------|----------------------------------------------------|--------------------------|---------------------------------------------------|
| $\alpha_0$ (%) | $\alpha_1$ (%) | $\beta_0$ (%) | $\beta_1$ (%) | $\gamma_0$ (2014 USD) | $\gamma_1$ (2014 USD) |
| 0.35 | $-0.0633358$ | 4.5 | 0.89 | 0.6289097 | 20.168 million | 67.968 million |

#### Results

The figures show results obtained by employing the parameters derived from the NHIS data. Figure 1 shows the projected path of smoking prevalence without any intervention (status-quo path) over the next 30 years versus the projected trajectory derived from an optimal combination of initiation and cessation interventions over the same time period (optimal path).

Figure 1 confirms that the numeric simulation is consistent with our theoretical results. With interventions, smoking prevalence decreases to 6.43% in 30 years versus the status quo of 8.54%. Figure 2 shows how the units of optimal interventions change over the 30-year span. The upper graph in Figure 2 shows the optimal units of initiation intervention over time while the lower one presents the optimal cessation units. We can see that both curves are monotonically increasing functions. In addition, both curves are convex. Convexity implies that as time goes on, the increases in units for both interventions accelerates.

Figure 3 shows the optimal cost ratio over time to achieve allocative efficiency. Based on our earlier
If $\gamma_1 u_1 > \gamma_2 u_2$, we should spend more money on initiation instead of cessation, and if not, we should spend more on cessation interventions. The figure indicates that for our example, we should always invest more on the US truth campaign and shift more emphasis to this prevention program over time. This result is due to a combination of program effectiveness and smoking prevalence. Parameter values in this numerical example can be easily adjusted to reflect different population characteristics and policy effectiveness. Figure 4 presents the total cost of interventions over time. To ensure we indeed derived optimal policy trajectories, we tested alternative interventions that yielded the same terminal smoking prevalence. All of them show higher costs than our optimal trajectories. One of them is here for illustration. The blue curve in the graph is the cost function for our optimal combination and the red curve is the one for the alternative combination. The area under the curve is the total amount of cost over 30 years; it is obvious that our optimal solution has a lower total cost. Similar results are obtained from the NSDUH data. We conducted a sensitivity analysis for the cost as well as the effectiveness of interventions and we found the results to be robust.

**Discussion**

This study establishes an optimal control model to investigate the best combination of smoking interventions to minimize smoking prevalence over 30 years while...
satisfying a budget constraint. By solving the model analytically using the Euler-Lagrange equation, we obtain a set of necessary conditions in forms of ODE. In addition, allocative efficiency is revealed in forms of the ratio between $g_1 u_1$ and $g_2 u_2$, which equals to

$$\frac{|\alpha_1| \gamma_2}{\beta_1 \gamma_1 s}.$$ 

The numerical simulations, based on interventions from the US truth campaign and the 12 + 12 weeks varenicline treatment combined with demographic data from NHIS and NSDUH, offer a few important observations.

First, this simulation example verifies our theoretical results. With optimal interventions, smoking prevalence is reduced to 6.43% in 30 years compared to the original 8.54% while satisfying the budget constraint of 1 billion US dollars over 30 years.

Next, we observe the optimal trajectories of intervention units. $u_1(t)$ and $u_2(t)$ both increase over time in the form of convex curves. This indicates that an optimal implementation strategy needs to expand initiation and cessation programs over time. Because the death rate is lower than the birth rate in the United States, our estimate of the optimal number of prevention units is a conservative one. We speculate that more emphasis should be put on prevention due to a growing population. In addition, the optimal ratio of costs changes as well. In this numerical example with the truth campaign and the varenicline treatment, the strategy is to always spend more money on prevention interventions and gradually shift more emphasis to prevention over time. On examination, these results seem logical. When we start with a substantial number of smokers in the population, it is important to encourage them to quit. When we have fewer smokers later on, the policy should shift more focus to prevention. The analytical form of the ratio is consistent with this intuition. Effectiveness of interventions, program costs, and smoking prevalence together determine the allocative efficiency between initiation and cessation programs. Here smoking prevalence is in the denominator, meaning the higher the prevalence, the more we should spend on cessation.

This study shows that optimal control methods can help us determine more efficient ways to address the smoking problem. The general framework established here can be applied to other problems in future research. Additionally, more features can be added when evaluating specific interventions. However, our study presents certain limitations. First, we employ a linear model of prevalence and constant policy effectiveness values. Linear ODEs are proven to be reasonable formulations for predicting smoking prevalence both domestically and globally. However, as prevalence declines, nonlinear effects might become more important in describing the system’s dynamics. Another limitation is that our formulation considers prevalence as a surrogate of population health effects, thus ignoring the timing differences between initiation and cessation related health benefits. Despite these limitations, our work presents a meaningful framework to analyze the issue of efficient allocation in tobacco control.

ORCID iD
Ruoyan Sun [i] https://orcid.org/0000-0001-8412-7727
References

1. Rigotti NA, Clair C. Managing tobacco use: the neglected cardiovascular disease risk factor. Eur Heart J. 2013;34(42):3259–67.
2. van Zyl Smit RN, Pai M, Yew WW, et al. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J. 2010;35(1):27–33.
3. Dunbar A, Gotjis W, Frishman W. Second-hand tobacco smoke and cardiovascular disease risk: an epidemiological review. Cardiol Rev. 2013;21(2):94–100.
4. US Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress. A Report of the Surgeon General. Atlanta: US Department of Health and Human Services; Centers for Disease Control and Prevention; National Center for Chronic Disease Prevention and Health Promotion; Office on Smoking and Health; 2014.
5. Xu X, Bishop EE, Kennedy SM, Simpson SA, Pechacek TF. Annual healthcare spending attributable to cigarette smoking: an update. Am J Prev Med. 2015;48(3):326–33.
6. Berman M, Crane R, Seiber E, Munur M. Estimating the cost of a smoking employee. Tob Control. 2014;23(5):428–33.
7. Kostova D, Ross H, Blecher E, Markowitz S. Is youth smoking responsive to cigarette prices? Evidence from low- and middle-income countries. Tob Control. 2011;20(6):419–24.
8. Coleman T, Chamberlain C, Davey MA, Cooper SE, Leonard-J-Bee J. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2015;(5):CD009329.
9. Free C, Knight R, Robertson S, et al. Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet. 2011;378(9785):49–55.
10. Schellack N, Bronkhorst E. Smoking cessation: review. S Afr Fam Pract. 2015;57(1):39–42.
11. Twyman L, Bonevski B, Paul C, Bryant J. Perceived barriers to smoking cessation in selected vulnerable groups: a systematic review of the qualitative and quantitative literature. BMJ Open. 2014;4(12):e006414.
12. Kim SS. A culturally adapted smoking cessation intervention for Korean Americans: preliminary findings. J Transcult Nurs. 2017;28(1):24–31.
13. Carpenter C, Cook PJ. Cigarette taxes and youth smoking: new evidence from national, state, and local Youth Risk Behavior Surveys. J Health Econ. 2008;27(2):287–99.
14. Campbell R, Starkey F, Holliday J, et al. An informal school-based peer-led intervention for smoking prevention in adolescence (ASSIST): a cluster randomised trial. Lancet. 2008;371(9624):1595–602.
15. Brown T, Platt S, Amos A. Equity impact of interventions and policies to reduce smoking in youth: systematic review. Tob Control. 2014;23(2):e98–e105.
16. Edwards R, Carter K, Peace J, Blakely T. An examination of smoking initiation rates by age: results from a large longitudinal study in New Zealand. Aust N Z J Public Health. 2013;37(6):516–9.
17. Azagba S, Baskerville NB, Minaker L. A comparison of adolescent smoking initiation measures on predicting future smoking behavior. Prev Med Rep. 2015;2:174–7.
18. Phillips E, Wang TW, Husten CG, et al. Tobacco product use among adults—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(44):1209–15.
19. Juusola J, Brandeau ML. HIV treatment and prevention: a simple model to determine optimal investment. Med Decis Making. 2016;36(3):391–409.
20. Basu S, Kiernan M. A simulation modeling framework to optimize programs using financial incentives to motivate health behavior change. Med Decis Making. 2016;36(1):48–58.
21. Mendez D, Alshanqeety O, Warner KE. The potential impact of smoking control policies on future global smoking trends. Tob Control. 2013;22(1):46–51.
22. Mendez D, Tam J, Giovino GA, Tsodikov A, Warner KE. Has smoking cessation increased? An examination of the US adult smoking cessation rate 1990–2014. Nicotine Tob Res. 2017;19(12):1418–24.
23. Kirk DE. Optimal Control Theory: An Introduction. Chelmsford (England): Courier Corporation; 2012.
24. Farrelly MC, Healton CG, Davis KC, Messeri P, Hersey JC, Haviland ML. Getting to the truth: evaluating national tobacco countermarketing campaigns. Am J Public Health. 2002;92(6):901–7.
25. Farrelly MC, Davis KC, Haviland ML, Messeri P, Healton CG. Evidence of a dose-response relationship between “truth” antismoking ads and youth smoking prevalence. Am J Public Health. 2005;95(3):425–31.
26. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008;179(2):135–44.
27. Knight C, Howard P, Baker CL, Marton JP. The cost-effectiveness of an extended course (12 + 12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health. 2010;13(2):209–14.
28. Centers for Disease Control and Prevention. Births and mortality. Available from: https://www.cdc.gov/nchs/fastats/births.htm
29. Centers for Disease Control and Prevention. Deaths and mortality. Available from: https://www.cdc.gov/nchs/fastats/deaths.htm